Aakaar Medical

Which are the latest news on Aakaar Medical?

Why is Aakaar Medical Technologies Ltd falling/rising?

As of 05-Sep, Aakaar Medical Technologies Ltd's stock price is at 62.70, down 0.48%, with significant declines of -14.98% year-to-date and -28.34% over the past year. The drop in investor participation and the stock's position relative to moving averages indicate a bearish trend contributing to the price decline.

As of 05-Sep, Aakaar Medical Technologies Ltd's stock price is falling, currently at 62.70, reflecting a change of -0.3 or -0.48%. This decline is consistent with the company's performance over various time periods, showing a significant drop of -14.98% year-to-date and -28.34% over the past year, compared to a lesser decline of -8.54% and -3.38% for the benchmark Sensex in the same periods. <BR><BR>Additionally, the stock has experienced a notable decrease in investor participation, with delivery volume on September 3 dropping by 77.27% against the 5-day average. This decline in trading activity suggests a lack of interest from investors, which could contribute to the downward pressure on the stock price. Furthermore, while the stock is currently higher than its 20-day moving average, it remains lower than the 5-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend in the short to medium term. Overall, these factors collectively explain the current decline in Aakaar Medical Technologies Ltd's stock price.

What does Aakaar Medical do?

Aakaar Medical Technologies Ltd is a micro-cap company in the healthcare services industry, incorporated in 2013 and converted to a public limited company in 2024. It has a market cap of INR 92 Cr, a P/E ratio of 14.00, and a return on equity of 12.17%.

Overview: <BR>Aakaar Medical Technologies Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>Aakaar Medical Technologies Ltd was originally incorporated as Aakaar Medical Technologies Private Limited in 2013. The company later converted its status to a public limited company, with the latest certificate of incorporation issued on November 18, 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 92 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity: 12.17% <BR>Price-to-Book: 1.68 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Aakaar Medical?

Aakaar Medical's peers include Choksi Laborator, Aspira Pathlab, Jeevan Scienti., Star Imaging, Royal Sense, and Shree Pacetronix. Aakaar Medical has a Good management risk and a 1-year return of -26.26%, significantly lower than its peers, with Royal Sense showing the highest return at 0.00%.

Peers: The peers of Aakaar Medical are Choksi Laborator, Aspira Pathlab, Jeevan Scienti., Star Imaging, Royal Sense, and Shree Pacetronix.<BR><BR>Quality Snapshot: Excellent management risk is observed at Star Imaging, Royal Sense, and Shree Pacetronix, while Good management risk is found at Aakaar Medical. Below Average management risk is present at Choksi Laborator, Aspira Pathlab, and Jeevan Scienti. Growth is Excellent at Royal Sense, Good at Aakaar Medical, Choksi Laborator, and Shree Pacetronix, and Below Average at Aspira Pathlab, Jeevan Scienti., and Star Imaging. Capital Structure is Excellent at Star Imaging, Good at Aakaar Medical, Royal Sense, and Shree Pacetronix, Average at Aspira Pathlab, and Below Average at Choksi Laborator and Jeevan Scienti.<BR><BR>Return Snapshot: Aakaar Medical's 1-year return is -26.26%, with Royal Sense having the highest return at 0.00% and Choksi Laborator, Aspira Pathlab, Jeevan Scienti., Star Imaging, and Shree Pacetronix also at 0.00%. Aakaar Medical's return is significantly lower than all peers. Additionally, there are no peers with a negative six-month return.

Is Aakaar Medical overvalued or undervalued?

As of November 17, 2025, Aakaar Medical is considered overvalued with a PE ratio of 18.23 and an EV to EBITDA ratio of 12.87, despite being lower than some peers like Sun Pharma and Divi's Lab, while its recent stock performance has underperformed the Sensex with returns of -3.24% over the past week and -11.37% over the past month.

As of 17 November 2025, Aakaar Medical's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. The PE ratio stands at 18.23, while the EV to EBITDA ratio is 12.87, and the ROCE is 15.34%. <BR><BR>In comparison to its peers, Aakaar Medical's PE ratio is significantly lower than that of Sun Pharma, which has a PE of 36.69, and Divi's Lab, which is at 69.78. However, it is higher than some peers like Dr. Reddy's Labs, which has a PE of 17.98. The recent performance shows that Aakaar Medical has underperformed the Sensex over the past week and month, with stock returns of -3.24% and -11.37%, respectively, reinforcing the notion of its overvaluation.